Role of tumor-associated macrophages in the acquisition of cancer cell stemness and its application for anti-tumor therapy
| Project/Area Number |
15K18435
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
Yoneda Akihiro 北海道大学, 産学・地域協働推進機構, 特任助教 (00451419)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 腫瘍マクロファージ / 癌幹細胞 / 幹細胞様特性 / 抗癌剤耐性 |
|---|
| Outline of Final Research Achievements |
Chemoresistance of cancer cells is a leading cause of chemotherapy and molecular target therapy against tumors. The purpose of the present study was to clarify the mechanism by which tumor-associated macrophages (TAMs) induce the acquisition of cancer cell stemness and promote the tumorigenic potential of cancer cells. Here we showed that IL-6 and HB-EGF derived from TAMs induce acquisition of cancer cell stemness and enhance the tumorigenicity of cancer cells. The tumorigenicity of cancer cells in mice that have IL-6-depleted or HB-EGF-depleted macrophages was significantly lower than that in wild-type mice. These results indicated that both IL-6 and HB-EGF derived from TAMs play a crucial role in cancer cell stemness and augment of tumorigenic potential of cancer cells, and suggested that targeted depletion of both IL-6 and HB-EGF may become a therapeutic modality for tumors.
|
Report
(4 results)
Research Products
(4 results)
